Եվրոպական Միություն -
բուլղարերեն -
EMA (European Medicines Agency)
symkevi
vertex pharmaceuticals (ireland) limited - tezacaftor, ivacaftor - Кистозна фиброза - Други продукти на дихателната система - symkevi is indicated in a combination regimen with ivacaftor tablets for the treatment of patients with cystic fibrosis (cf) aged 6 years and older who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t.
Եվրոպական Միություն -
բուլղարերեն -
EMA (European Medicines Agency)
verzenios
eli lilly nederland b.v. - abemaciclib - Неоплазми на гърдата - Антинеопластични средства - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.
Եվրոպական Միություն -
բուլղարերեն -
EMA (European Medicines Agency)
senstend
plethora pharma solutions limited - лидокаин, prilocaine - Преждевременна Еякулация - Анестезиология - senstend е показан за лечение на първична преждевременна еякулация при възрастни мъже.
Եվրոպական Միություն -
բուլղարերեն -
EMA (European Medicines Agency)
nilemdo
daiichi sankyo europe gmbh - bempedoic киселина - hypercholesterolemia; dyslipidemias - Липидни модифициращи агенти - nilemdo е показан при възрастни пациенти с първична хиперхолестеролемия (гетерозиготная семейна и не наследена) или смесени дислипидемии като допълнение към диета в комбинация със статин или статин с други гиполипидемической терапия при пациенти не са в състояние да постигнат ldl с целите си с възможно най-переносимой дози статини (виж раздели 4. 2, 4. 3 и 4. 4) или отделно или в комбинация с друг гиполипидемической терапия при пациенти статин нетолерантно, или за някой друг статин противопоказан.
Եվրոպական Միություն -
բուլղարերեն -
EMA (European Medicines Agency)
nustendi
daiichi sankyo europe gmbh - bempedoic киселина, эзетимиб - hypercholesterolemia; dyslipidemias - Липидни модифициращи агенти - nustendi е показан при възрастни пациенти с първична хиперхолестеролемия (гетерозиготная семейна и не наследена) или смесени дислипидемии като допълнение към диета в комбинация със статин при пациенти не са в състояние да постигнат ldl холестерола с цел максимално переносимой доза статин в допълнение към ezetimibealone при пациенти, които са или статин непоносимост или за някой друг статин е противопоказана и не може да се постигне ldl холестерола с цел эзетимибом сам,при пациенти вече лекувани с комбинация bempedoic киселина и эзетимиб като отделни таблетки с или без статин.
Եվրոպական Միություն -
բուլղարերեն -
EMA (European Medicines Agency)
kaftrio
vertex pharmaceuticals (ireland) limited - ivacaftor, tezacaftor, elexacaftor - Кистозна фиброза - Други продукти на дихателната система - kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.
Եվրոպական Միություն -
բուլղարերեն -
EMA (European Medicines Agency)
leqvio
novartis europharm limited - inclisiran - hypercholesterolemia; dyslipidemias - Липидни модифициращи агенти - leqvio is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin, oralone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.
Եվրոպական Միություն -
բուլղարերեն -
EMA (European Medicines Agency)
enhertu
daiichi sankyo europe gmbh - trastuzumab deruxtecan - Неоплазми на гърдата - Антинеопластични средства - breast cancerher2-positive breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-positive breast cancer who have received one or more prior anti-her2-based regimens. her2-low breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4. non-small cell lung cancer (nsclc)enhertu as monotherapy is indicated for the treatment of adult patients with advanced nsclc whose tumours have an activating her2 (erbb2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. gastric cancerenhertu as monotherapy is indicated for the treatment of adult patients with advanced her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma who have received a prior trastuzumab-based regimen.
Եվրոպական Միություն -
բուլղարերեն -
EMA (European Medicines Agency)
lutetium (177lu) chloride billev (previously illuzyce)
billev pharma aps - lutetium (177lu) chloride - Радиоюклидно изображение - Терапевтични радиофармацевтици - lutetium (177lu) chloride billev is a radiopharmaceutical precursor, and it is not intended for direct use in patients. it is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with lutetium (177lu) chloride.
